Breno S Diniz1, Antonio L Teixeira2, Rodrigo Machado-Vieira3, Leda L Talib4, Marcia Radanovic4, Wagner F Gattaz4, Orestes V Forlenza4. 1. brenosatler@gmail.com. 2. Department of Internal Medicine, Faculty of Medicine, Federal University of Minas Gerais, Belo Horizonte, Brazil. 3. Department and Institute of Psychiatry, Faculty of Medicine, University of São Paulo, Brazil. National Institute of Mental Health (NIMH), National Institutes of Health, Bethesda, Maryland. 4. Department and Institute of Psychiatry, Faculty of Medicine, University of São Paulo, Brazil.
Abstract
OBJECTIVES: Late-life depression (LLD) is associated with reduced neurotrophic support and abnormalities in neurodegenerative cascades. The aim of the present study is to determine the concentrations of brain-derived neurotrophic factor (BDNF), amyloid-β42, total Tau, and phosphorylated Tau in the cerebrospinal fluid (CSF) of patients with LLD and cognitive impairment compared to healthy older adults. METHOD: We included 25 antidepressant-free patients with LLD (10 with mild cognitive impairment [LLD + MCI] and 15 with no cognitive decline [LLD + NCD]) and 25 healthy older adults as a comparison group. Depressive symptoms were assessed by the 21-item Hamilton Depression Rating Scale (HDRS-21) and cognitive performance by a comprehensive cognitive battery. RESULTS: Patients with LLD + MCI showed significantly lower CSF BDNF levels compared to LLD + NCD and healthy controls (p = .003). There were no significant differences in Alzheimer's disease-related CSF biomarkers between groups. CSF BDNF concentrations were positively correlated with Cambridge Cognitive Test (CAMCOG) scores (r = .36, p = .02). DISCUSSION: The present study adds to the growing body of evidence that abnormalities in the BDNF system are involved in the pathophysiology of LLD. The reduction of the availability of BDNF in the central nervous system may indicate increased vulnerability to the development of several age-related neuropsychiatric disorders as well as to adverse cognitive outcomes.
OBJECTIVES: Late-life depression (LLD) is associated with reduced neurotrophic support and abnormalities in neurodegenerative cascades. The aim of the present study is to determine the concentrations of brain-derived neurotrophic factor (BDNF), amyloid-β42, total Tau, and phosphorylated Tau in the cerebrospinal fluid (CSF) of patients with LLD and cognitive impairment compared to healthy older adults. METHOD: We included 25 antidepressant-free patients with LLD (10 with mild cognitive impairment [LLD + MCI] and 15 with no cognitive decline [LLD + NCD]) and 25 healthy older adults as a comparison group. Depressive symptoms were assessed by the 21-item Hamilton Depression Rating Scale (HDRS-21) and cognitive performance by a comprehensive cognitive battery. RESULTS:Patients with LLD + MCI showed significantly lower CSF BDNF levels compared to LLD + NCD and healthy controls (p = .003). There were no significant differences in Alzheimer's disease-related CSF biomarkers between groups. CSF BDNF concentrations were positively correlated with Cambridge Cognitive Test (CAMCOG) scores (r = .36, p = .02). DISCUSSION: The present study adds to the growing body of evidence that abnormalities in the BDNF system are involved in the pathophysiology of LLD. The reduction of the availability of BDNF in the central nervous system may indicate increased vulnerability to the development of several age-related neuropsychiatric disorders as well as to adverse cognitive outcomes.
Authors: Breno S Diniz; Antonio L Teixeira; Aline S Miranda; Leda L Talib; Wagner F Gattaz; Orestes V Forlenza Journal: J Psychiatr Res Date: 2011-10-01 Impact factor: 4.791
Authors: Nunzio Pomara; Davide Bruno; Antero S Sarreal; Raymundo T Hernando; Jay Nierenberg; Eva Petkova; John J Sidtis; Thomas M Wisniewski; Pankaj D Mehta; Domenico Pratico; Henrik Zetterberg; Kaj Blennow Journal: Am J Psychiatry Date: 2012-05 Impact factor: 18.112
Authors: Breno Satler Diniz; Charles F Reynolds; Amy Begley; Mary Amanda Dew; Stewart J Anderson; Francis Lotrich; Kirk I Erickson; Oscar Lopez; Howard Aizenstein; Etienne L Sibille; Meryl A Butters Journal: J Psychiatr Res Date: 2013-11-20 Impact factor: 4.791
Authors: Breno S Diniz; Meryl A Butters; Steven M Albert; Mary Amanda Dew; Charles F Reynolds Journal: Br J Psychiatry Date: 2013-05 Impact factor: 9.319
Authors: Breno S Diniz; Antonio L Teixeira; Rodrigo Machado-Vieira; Leda L Talib; Wagner F Gattaz; Orestes V Forlenza Journal: Am J Geriatr Psychiatry Date: 2013-02-06 Impact factor: 4.105
Authors: Christos Tsopelas; Robert Stewart; George M Savva; Carol Brayne; Paul Ince; Alan Thomas; Fiona E Matthews Journal: Br J Psychiatry Date: 2011-02 Impact factor: 9.319
Authors: Apoorva Bhandari; Jennifer I Lissemore; Tarek K Rajji; Benoit H Mulsant; Robin F H Cash; Yoshihiro Noda; Reza Zomorrodi; Jordan F Karp; Eric J Lenze; Charles F Reynolds; Zafiris J Daskalakis; Daniel M Blumberger Journal: J Psychiatr Res Date: 2018-08-31 Impact factor: 4.791
Authors: Nunzio Pomara; Davide Bruno; Ricardo S Osorio; Chelsea Reichert; Jay Nierenberg; Antero S Sarreal; Raymundo T Hernando; Charles R Marmar; Thomas Wisniewski; Henrik Zetterberg; Kaj Blennow Journal: Neuroreport Date: 2016-09-28 Impact factor: 1.837
Authors: Kenia Kelly Fiaux do Nascimento; Kelly P Silva; Leandro F Malloy-Diniz; Meryl A Butters; Breno S Diniz Journal: J Psychiatr Res Date: 2015-07-26 Impact factor: 4.791
Authors: Scott E Counts; Bin He; John G Prout; Bernadeta Michalski; Lucia Farotti; Margaret Fahnestock; Elliott J Mufson Journal: Curr Alzheimer Res Date: 2016 Impact factor: 3.498
Authors: Breno Satler Diniz; Chien-Wei Lin; Etienne Sibille; George Tseng; Francis Lotrich; Howard J Aizenstein; Charles F Reynolds; Meryl A Butters Journal: J Psychiatr Res Date: 2016-07-11 Impact factor: 5.250